Immunocore Reports Full Year 2021 Financial Results and Provides Business Update
03 mars 2022 07h00 HE
|
Immunocore Holdings Limited
PRESS RELEASE Immunocore Reports Full Year 2021 Financial Results and Provides Business Update KIMMTRAK® (tebentafusp-tebn) approved by the FDA for the treatment of unresectable or metastatic...
Immunocore announces FDA approval of KIMMTRAK® (tebentafusp-tebn) for the treatment of unresectable or metastatic uveal melanoma
26 janv. 2022 07h00 HE
|
Immunocore Holdings Limited
Immunocore announces FDA approval of KIMMTRAK® (tebentafusp-tebn) for the treatment of unresectable or metastatic uveal melanomaKIMMTRAK is the first and only FDA approved therapy for the treatment of...
Immunocore to present at upcoming investor conferences
27 mai 2021 16h30 HE
|
Immunocore Holdings Limited
PRESS RELEASE Immunocore to present at upcoming investor conferences (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 27 May 2021) Immunocore (Nasdaq: IMCR), a late-stage...